Literature DB >> 21448929

Functionally significant nicotine acetylcholine receptor subunit α5 promoter haplotypes are associated with susceptibility to lung cancer in Chinese.

Xia Zheng1, Wenyuan Duan, Jing Xu, Chenxia Nie, Zhangmin Yang, Hongyan Wang, Weimin Wang, Daru Lu.   

Abstract

BACKGROUND: Although recent genome-wide association studies have been conducted to reveal the relation between variations in the α5 nicotinic receptor subunit and lung cancer in European and American populations, to the authors' knowledge, no definite information on the role of nicotine acetylcholine receptor subunit α5 (CHRNA5) in lung cancer risk has been obtained in a Chinese population.
METHODS: To test this possible association, a case-control study was conducted in 505 patients with lung cancer (cases) and a control group of 498 cancer-free individuals.
RESULTS: Participants were screened for variations in the CHRNA5 promoter region by sequencing, and 2 common polymorphisms were selected at -1640 (reference single nucleotide polymorphism identifier rs3829787 cytosine to thymine [C→T]) and at -62 (rs3841324 insertion→deletion [ins→del]) from the transcription start site of the CHRNA5 gene. Haplotype analysis revealed that the 2 least frequent haplotypes (T/ins and C/del) were statistically protective against lung cancer (P = .0002 and P = .0094, respectively). Unexpectedly, the luciferase results indicated that these 2 protective haplotype constructs had the extremely opposite promoter activity in various cells: the T/ins haplotype had the highest activity and the C/del haplotype had the lowest activity. Surface plasmon resonance demonstrated that both minor alleles (T and del) decreased DNA binding affinity to nuclear extracts, which the authors presumed was responsible for the disparity in promoter activity.
CONCLUSIONS: The current results indicated that the CHRNA5 gene with under-activated or over-activated promoter activity may be protective against lung cancer. These results indicated a new associated risk pattern between CHRNA5 promoter activity and susceptibility to lung cancer that implies a complex role of the CHRNA5 gene in lung cancer.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21448929     DOI: 10.1002/cncr.26017

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  A case-control study of a sex-specific association between a 15q25 variant and lung cancer risk.

Authors:  Chongjuan Wei; Younghun Han; Margaret R Spitz; Xifeng Wu; Haidee Chancoco; Pinchas Akiva; Gideon Rechavi; Hadar Brand; Issac Wun; Marsha L Frazier; Christopher I Amos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10-25       Impact factor: 4.254

2.  Nicotinic cholinergic receptors in esophagus: Early alteration during carcinogenesis and prognostic value.

Authors:  Marina Chianello Nicolau; Luis Felipe Ribeiro Pinto; Pedro Nicolau-Neto; Paulo Roberto Alves de Pinho; Ana Rossini; Tatiana de Almeida Simão; Sheila Coelho Soares Lima
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

Review 3.  Connections of nicotine to cancer.

Authors:  Sergei A Grando
Journal:  Nat Rev Cancer       Date:  2014-05-15       Impact factor: 60.716

4.  Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.

Authors:  David P King; Sara Paciga; Eve Pickering; Neal L Benowitz; Laura J Bierut; David V Conti; Jaakko Kaprio; Caryn Lerman; Peter W Park
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

5.  Role of a genetic variant on the 15q25.1 lung cancer susceptibility locus in smoking-associated nasopharyngeal carcinoma.

Authors:  Xuemei Ji; Weidong Zhang; Jiang Gui; Xia Fan; Weiwei Zhang; Yafang Li; Guangyu An; Dakai Zhu; Qiang Hu
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

6.  Variation in the α 5 nicotinic acetylcholine receptor subunit gene predicts cigarette smoking intensity as a function of nicotine content.

Authors:  D A Macqueen; B W Heckman; M D Blank; K Janse Van Rensburg; J Y Park; D J Drobes; D E Evans
Journal:  Pharmacogenomics J       Date:  2013-01-29       Impact factor: 3.550

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.